FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer
November 14, 2022 11:41 amby Kristi Rosa
At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA